9 citations
,
August 2023 in “Molecules” This study found that the peptides RMYYY and VMYMI displayed stronger binding energy and more frequent interactions with HPGDS compared to the native inhibitor, suggesting potential as future therapeutic drugs.
5 citations
,
January 2014 in “Molecular Simulation” This study discovered a potential new 5α-reductase type II inhibitor with higher predicted activity than finasteride, suggesting it as a promising candidate for treating benign prostatic hyperplasia.
4 citations
,
August 2022 in “The Scientific World Journal” This study found that bufotalinin, derived from Merremia peltata leaves, may enhance hair growth by acting as a potential androgen receptor antagonist in rabbits.
2 citations
,
July 2025 in “Discover Chemistry.” This study explored the optimization of phytochemicals from Alstonia boonei to develop potential 5-alpha reductase inhibitors for Benign Prostatic Hyperplasia, finding promising analogs with enhanced binding affinity and stability compared to Finasteride, warranting further experimental validation.
2 citations
,
April 2023 in “Pharmaceuticals” This study evaluated the anti-alopecia activity of compounds from Merremia peltata leaf in rabbits and found that scopolin has a promising effect on hair growth and androgen receptor affinity, potentially offering a new treatment option for alopecia.